Breast Cancer Information
Digital Infrared Thermal Imaging In Medical Therapy
Digital technology now makes Digital Infrared Thermal Imaging available to all. There now is a completely safe test that can aid in diagnosis, treatment and monitoring with absolutely no risk or radiation exposure.
Early Detection And Breast Cancer
It is generally accepted that by the time a cancer is found by mammography or palpated during a clinical breast exam, the cancer has been growing for 8-10 years. What if we could have been alerted to the problem as it was developing, rather than wait till it is large enough to be seen by the naked eye? Would that be of interest to you?There exists a technology that can detect an issue YEARS before a tumor can be seen on X-ray or palpated during an exam.
My First Thermographic Experience
I had been a bit nervous all day wondering what my thermogram procedure would entail. Would I need to undress completely? Would I be given one of those paper gowns that opens in the front and barely covers me? Would there be any heat coming out of the camera? I had been avoiding a mammogram after reading the latest information about the risks associated with X-ray; knowing that I was potentially putting myself at greater risk by not taking charge of my health.
New Advances In Early Breast Cancer Detection
In November 2003, the American Cancer Society stated that breast cancer is the leading cause of death in women between the ages of 40 and 44. In the United States, there are approximately 200,000 new cases of breast cancer and more than 40,000 deaths; making the U.
Recommendations For Early Breast Cancer Screening
Women need to empower themselves about the benefits and risks of mammography and examine the additional screening tools available today. One current philosophy suggests breast health screening should begin at age 25.
FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer
Today, as part of Project Orbis, the U.S. Food and Drug Administration approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can't be removed with surgery, or has spread to other parts of the body, including the brain, and who have received one or more prior treatments.